Dr. Elaine Breslin:

One of the roles of the HPRA is authorising clinical trials. We are aware there are ongoing trials with Epidiolex, which is the CBD enriched standardised product. Dr. Doherty referred to those.

It is likely that trials would not be conducted in Ireland alone but that we would participate in international trials, such as those being conducted by the GW Pharmaceuticals company, and Irish patients and Irish investigators could participate in those trials. Such trials would be authorised by the HPRA for conduct in Ireland. Were those trials to be submitted here, it is likely that this experience would build confidence among investigators and patients. The HPRA would be very open to receiving those trail applications.